Immunosurveillance and immunotherapy of tumors by innate immune cells

Current Opinion in Immunology

Volumn 38, Issue , 2016, Pages 52-58

  Iannello, Alexandre ^a   Thompson, Thornton W ^a   Ardolino, Michele ^a   Marcus, Assaf ^a   Raulet, David H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD226 ANTIGEN; DECTIN 1; DNA; MAJOR HISTOCOMPATIBILITY ANTIGEN; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2D; UNCLASSIFIED DRUG; T LYMPHOCYTE ANTIGEN; TUMOR PROTEIN;

ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; B CELL LYMPHOMA; BONE MARROW CELL; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CYTOSOL; FIBROSARCOMA; HUMAN; IMMUNOSURVEILLANCE; INNATE IMMUNITY; MACROPHAGE; NONHUMAN; PHAGOCYTOSIS; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION; REVIEW; SARCOMA; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; UPREGULATION; ANIMAL; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; NATURAL KILLER CELL; NEOPLASMS; PATHOLOGY; PROCEDURES; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; DNA, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC SURVEILLANCE; IMMUNOTHERAPY; KILLER CELLS, NATURAL; MACROPHAGES; NEOPLASM PROTEINS; NEOPLASMS; RECEPTORS, NATURAL KILLER CELL; SIGNAL TRANSDUCTION;

EID: 84949437115     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2015.11.001     Document Type: Review

References (73)

1. Raulet D.H. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 2003, 3:781-790.
2. Raulet D.H., Gasser S., Gowen B.G., Deng W., Jung H. Regulation of ligands for the NKG2D activating receptor. Ann Rev Immunol 2013, 31:413-441.
3. Groh V., Rhinehart R., Secrist H., Bauer S., Grabstein K.H., Spies T. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci USA 1999, 96:6879-6884.
4. Cerwenka A., Bakker A.B.H., McClanahan T., Wagner J., Wu J., Phillips J.H., Lanier L.L. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity 2000, 12:721-727.
5. Diefenbach A., Jamieson A.M., Liu S.D., Shastri N., Raulet D.H. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat Immunol 2000, 1:119-126.
6. Diefenbach A., Jensen E.R., Jamieson A.M., Raulet D.H. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 2001, 413:165-171.
7. Cerwenka A., Baron J.L., Lanier L.L. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc Natl Acad Sci USA 2001, 98:11521-11526.
8. Guerra N., Tan Y.X., Joncker N.T., Choy A., Gallardo F., Xiong N., Knoblaugh S., Cado D., Greenberg N.R., Raulet D.H. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 2008, 28:571-580.
9. Chitadze G., Bhat J., Lettau M., Janssen O., Kabelitz D. Generation of soluble NKG2D ligands: proteolytic cleavage, exosome secretion and functional implications. Scand J Immunol 2013, 78:120-129.
10. Fernandez-Messina L., Ashiru O., Boutet P., Aguera-Gonzalez S., Skepper J.N., Reyburn H.T., Vales-Gomez M. Differential mechanisms of shedding of the glycosyl-phosphatidylinositol (GPI)-anchored NKG2D ligands. J Biol Chem 2010, 285:8543-8551.
11. Groh V., Wu J., Yee C., Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002, 419:734-738.
12. Song H., Kim J., Cosman D., Choi I. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression. Cell Immunol 2006, 239:22-30.
13. Deng W., Gowen B.G., Zhang L., Wang L., Lau S., Iannello A., Xu J., Rovis T.L., Xiong N., Raulet D.H. Antitumor immunity. A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection. Science 2015, 348:136-139.
14. Viaud S., Terme M., Flament C., Taieb J., Andre F., Novault S., Escudier B., Robert C., Caillat-Zucman S., Tursz T., et al. Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha. PLoS ONE 2009, 4:e4942.
15. Kruse P.H., Matta J., Ugolini S., Vivier E. Natural cytotoxicity receptors and their ligands. Immunol Cell Biol 2014, 92:221-229.
16. Brandt C.S., Baratin M., Yi E.C., Kennedy J., Gao Z., Fox B., Haldeman B., Ostrander C.D., Kaifu T., Chabannon C., et al. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med 2009, 206:1495-1503.
17. Kaifu T., Escaliere B., Gastinel L.N., Vivier E., Baratin M. B7-H6/NKp30 interaction: a mechanism of alerting NK cells against tumors. Cell Mol Life Sci 2011, 68:3531-3539.
18. Pogge von Strandmann E., Simhadri V.R., von Tresckow B., Sasse S., Reiners K.S., Hansen H.P., Rothe A., Boll B., Simhadri V.L., Borchmann P., et al. Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity 2007, 27:965-974.
19. Simhadri V.R., Reiners K.S., Hansen H.P., Topolar D., Simhadri V.L., Nohroudi K., Kufer T.A., Engert A., Pogge von Strandmann E. Dendritic cells release HLA-B-associated transcript-3 positive exosomes to regulate natural killer function. PLoS ONE 2008, 3:e3377.
20. Glasner A., Ghadially H., Gur C., Stanietsky N., Tsukerman P., Enk J., Mandelboim O. Recognition and prevention of tumor metastasis by the NK receptor NKp46/NCR1. J Immunol 2012, 188:2509-2515.
21. Halfteck G.G., Elboim M., Gur C., Achdout H., Ghadially H., Mandelboim O. Enhanced in vivo growth of lymphoma tumors in the absence of the NK-activating receptor NKp46/NCR1. J Immunol 2009, 182:2221-2230.
22. Bryceson Y.T., March M.E., Barber D.F., Ljunggren H.G., Long E.O. Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells. J Exp Med 2005, 202:1001-1012.
23. Shibuya A., Campbell D., Hannum C., Yssel H., Franz-Bacon K., McClanahan T., Kitamura T., Nicholl J., Sutherland G.R., Lanier L.L., et al. DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity 1996, 4:573-581.
24. Bottino C., Castriconi R., Pende D., Rivera P., Nanni M., Carnemolla B., Cantoni C., Grassi J., Marcenaro S., Reymond N., et al. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med 2003, 198:557-567.
25. Tahara-Hanaoka S., Shibuya K., Onoda Y., Zhang H., Yamazaki S., Miyamoto A., Honda S., Lanier L.L., Shibuya A. Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112). Int Immunol 2004, 16:533-538.
26. Croxford J.L., Tang M.L., Pan M.F., Huang C.W., Kamran N., Phua C.M., Chng W.J., Ng S.B., Raulet D.H., Gasser S. ATM-dependent spontaneous regression of early Emu-myc-induced murine B-cell leukemia depends on natural killer and T cells. Blood 2013, 121:2512-2521.
27. Guillerey C., Ferrari de Andrade L., Vuckovic S., Miles K., Ngiow S.F., Yong M.C., Teng M.W., Colonna M., Ritchie D.S., Chesi M., et al. Immunosurveillance and therapy of multiple myeloma are CD226 dependent. J Clin Invest 2015, 125:2077-2089.
28. Gilfillan S., Chan C.J., Cella M., Haynes N.M., Rapaport A.S., Boles K.S., Andrews D.M., Smyth M.J., Colonna M. DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. J Exp Med 2008, 205:2965-2973.
29. Iguchi-Manaka A., Kai H., Yamashita Y., Shibata K., Tahara-Hanaoka S., Honda S., Yasui T., Kikutani H., Shibuya K., Shibuya A. Accelerated tumor growth in mice deficient in DNAM-1 receptor. J Exp Med 2008, 205:2959-2964.
30. Tahara-Hanaoka S., Shibuya K., Kai H., Miyamoto A., Morikawa Y., Ohkochi N., Honda S., Shibuya A. Tumor rejection by the poliovirus receptor family ligands of the DNAM-1 (CD226) receptor. Blood 2006, 107:1491-1496.
31. Chan C.J., Andrews D.M., McLaughlin N.M., Yagita H., Gilfillan S., Colonna M., Smyth M.J. DNAM-1/CD155 interactions promote cytokine and NK cell-mediated suppression of poorly immunogenic melanoma metastases. J Immunol 2010, 184:902-911.
32. Soriani A., Zingoni A., Cerboni C., Iannitto M.L., Ricciardi M.R., Di Gialleonardo V., Cippitelli M., Fionda C., Petrucci M.T., Guarini A., et al. ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood 2009, 113:3503-3511.
33. Soriani A., Iannitto M.L., Ricci B., Fionda C., Malgarini G., Morrone S., Peruzzi G., Ricciardi M.R., Petrucci M.T., Cippitelli M., et al. Reactive oxygen species- and DNA damage response-dependent NK cell activating ligand upregulation occurs at transcriptional levels and requires the transcriptional factor E2F1. J Immunol 2014, 193:950-960.
34. Fionda C., Abruzzese M.P., Zingoni A., Soriani A., Ricci B., Molfetta R., Paolini R., Santoni A., Cippitelli M. Nitric oxide donors increase PVR/CD155 DNAM-1 ligand expression in multiple myeloma cells: role of DNA damage response activation. BMC Cancer 2015, 15:17.
35. Karre K., Ljunggren H.G., Piontek G., Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defense strategy. Nature 1986, 319:675-678.
36. Ljunggren H-G., Karre K. Host resistance directed selectively against H-2-deficient lymphoma variants. J Exp Med 1985, 162:1745-1759.
37. Raulet D.H., Vance R.E. Self-tolerance of natural killer cells. Nat Rev Immunol 2006, 6:520-531.
38. Tu M.M., Mahmoud A.B., Wight A., Mottashed A., Belanger S., Rahim M.M., Abou-Samra E., Makrigiannis A.P. Ly49 family receptors are required for cancer immunosurveillance mediated by natural killer cells. Cancer Res 2014, 74:3684-3694.
39. Andrews D.M., Sullivan L.C., Baschuk N., Chan C.J., Berry R., Cotterell C.L., Lin J., Halse H., Watt S.V., Poursine-Laurent J., et al. Recognition of the nonclassical MHC class I molecule H2-M3 by the receptor Ly49A regulates the licensing and activation of NK cells. Nat Immunol 2012, 13:1171-1177.
40. Garrido F., Algarra I. MHC antigens and tumor escape from immune surveillance. Adv Cancer Res 2001, 83:117-158.
41. Ardolino M., Azimi C.S., Iannello A., Trevino T.N., Horan L., Zhang L., Deng W., Ring A.M., Fischer S., Garcia K.C., et al. Cytokine therapy reverses NK cell anergy in MHC-deficient tumors. J Clin Invest 2014, 124:4781-4794.
42. Chiba S., Ikushima H., Ueki H., Yanai H., Kimura Y., Hangai S., Nishio J., Negishi H., Tamura T., Saijo S., et al. Recognition of tumor cells by Dectin-1 orchestrates innate immune cells for anti-tumor responses. eLife 2014, 3:e04177.
43. Taylor P.R., Tsoni S.V., Willment J.A., Dennehy K.M., Rosas M., Findon H., Haynes K., Steele C., Botto M., Gordon S., et al. Dectin-1 is required for beta-glucan recognition and control of fungal infection. Nat Immunol 2007, 8:31-38.
44. Chao M.P., Majeti R., Weissman I.L. Programmed cell removal: a new obstacle in the road to developing cancer. Nat Rev Cancer 2012, 12:58-67.
45. Henson P.M., Hume D.A. Apoptotic cell removal in development and tissue homeostasis. Trends Immunol 2006, 27:244-250.
46. Gardai S.J., McPhillips K.A., Frasch S.C., Janssen W.J., Starefeldt A., Murphy-Ullrich J.E., Bratton D.L., Oldenborg P.A., Michalak M., Henson P.M. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 2005, 123:321-334.
47. Chao M.P., Jaiswal S., Weissman-Tsukamoto R., Alizadeh A.A., Gentles A.J., Volkmer J., Weiskopf K., Willingham S.B., Raveh T., Park C.Y., et al. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med 2010, 2:63ra94.
48. Willingham S.B., Volkmer J.P., Gentles A.J., Sahoo D., Dalerba P., Mitra S.S., Wang J., Contreras-Trujillo H., Martin R., Cohen J.D., et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci USA 2012, 109:6662-6667.
49. Wu J., Sun L., Chen X., Du F., Shi H., Chen C., Chen Z.J. Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science 2013, 339:826-830.
50. Cai X., Chiu Y.H., Chen Z.J. The cGAS-cGAMP-STING pathway of cytosolic DNA sensing and signaling. Mol Cell 2014, 54:289-296.
51. Shen Y.J., Le Bert N., Chitre A.A., Koo C.X., Nga X.H., Ho S.S., Khatoo M., Tan N.Y., Ishii K.J., Gasser S. Genome-derived cytosolic DNA mediates type I interferon-dependent rejection of B cell lymphoma cells. Cell Rep 2015, 11:460-473.
52. Lam A.R., Le Bert N., Ho S.S., Shen Y.J., Tang M.L., Xiong G.M., Croxford J.L., Koo C.X., Ishii K.J., Akira S., et al. RAE1 ligands for the NKG2D receptor are regulated by STING-dependent DNA sensor pathways in lymphoma. Cancer research 2014, 74:2193-2203.
53. Woo S.R., Fuertes M.B., Corrales L., Spranger S., Furdyna M.J., Leung M.Y., Duggan R., Wang Y., Barber G.N., Fitzgerald K.A., et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 2014, 41:830-842.
54. Diefenbach A., Hsia J.K., Hsiung M.Y., Raulet D.H. A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity. Eur J Immunol 2003, 33:381-391.
55. Jung H., Hsiung B., Pestal K., Procyk E., Raulet D.H. RAE-1 ligands for the NKG2D receptor are regulated by E2F transcription factors, which control cell cycle entry. J Exp Med 2012, 209:2409-2422.
56. Groh V., Bahram S., Bauer S., Herman A., Beauchamp M., Spies T. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci USA 1996, 93:12445-12450.
57. Venkataraman G.M., Suciu D., Groh V., Boss J.M., Spies T. Promoter region architecture and transcriptional regulation of the genes for the MHC class I-related chain A and B ligands of NKG2D. J Immunol 2007, 178:961-969.
58. Li H., Lakshmikanth T., Garofalo C., Enge M., Spinnler C., Anichini A., Szekely L., Karre K., Carbone E., Selivanova G. Pharmacological activation of p53 triggers anticancer innate immune response through induction of ULBP2. Cell Cycle 2011, 10:3346-3358.
59. Textor S., Fiegler N., Arnold A., Porgador A., Hofmann T.G., Cerwenka A. Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2. Cancer Res 2011, 71:5998-6009.
60. Molinero L.L., Fuertes M.B., Girart M.V., Fainboim L., Rabinovich G.A., Costas M.A., Zwirner N.W. NF-kappa B regulates expression of the MHC class I-related chain A gene in activated T lymphocytes. J Immunol 2004, 173:5583-5590.
61. Lin D., Lavender H., Soilleux E.J., O'Callaghan C.A. NF-kappaB regulates MICA gene transcription in endothelial cell through a genetically inhibitable control site. J Biol Chem 2012, 287:4299-4310.
62. Gowen B.G., Chim B., Marceau C.D., Greene T.T., Burr P., Gonzalez J.R., Hesser C.R., Dietzen P.A., Russell T., Iannello A., et al. A forward genetic screen reveals novel independent regulators of ULBP1, an activating ligand for natural killer cells. eLife 2015, 4:e08474.
63. Cerboni C., Zingoni A., Cippitelli M., Piccoli M., Frati L., Santoni A. Antigen-activated human T lymphocytes express cell-surface NKG2D ligands via an ATM/ATR-dependent mechanism and become susceptible to autologous NK- cell lysis. Blood 2007, 110:606-615.
64. Gasser S., Orsulic S., Brown E.J., Raulet D.H. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 2005, 436:1186-1190.
65. Gourzi P., Leonova T., Papavasiliou F.N. A Role for activation-induced cytidine deaminase in the host response against a transforming retrovirus. Immunity 2006, 24:779-786.
66. Ward J., Davis Z., DeHart J., Zimmerman E., Bosque A., Brunetta E., Mavilio D., Planelles V., Barker E. HIV-1 Vpr triggers natural killer cell-mediated lysis of infected cells through activation of the ATR-mediated DNA damage response. PLoS Pathog 2009, 5:e1000613.
67. Norman J.M., Mashiba M., McNamara L.A., Onafuwa-Nuga A., Chiari-Fort E., Shen W., Collins K.L. The antiviral factor APOBEC3G enhances the recognition of HIV-infected primary T cells by natural killer cells. Nat Immunol 2011, 12:975-983.
68. Stern-Ginossar N., Gur C., Biton M., Horwitz E., Elboim M., Stanietsky N., Mandelboim M., Mandelboim O. Human microRNAs regulate stress-induced immune responses mediated by the receptor NKG2D. Nat Immunol 2008, 9:1065-1073.
69. Tokuyama M., Lorin C., Delebecque F., Jung H., Raulet D.H., Coscoy L. Expression of the RAE-1 family of stimulatory NK-cell ligands requires activation of the PI3 K pathway during viral infection and transformation. PLoS Pathog 2011, 7:e1002265.
70. Liu X.V., Ho S.S., Tan J.J., Kamran N., Gasser S. Ras activation induces expression of raet1 family NK receptor ligands. J Immunol 2012, 189:1826-1834.
71. Routes J.M., Ryan S., Morris K., Takaki R., Cerwenka A., Lanier L.L. Adenovirus serotype 5 E1A sensitizes tumor cells to NKG2D-dependent NK cell lysis and tumor rejection. J Exp Med 2005, 202:1477-1482.
72. Nice T.J., Coscoy L., Raulet D.H. Posttranslational regulation of the NKG2D ligand Mult1 in response to cell stress. J Exp Med 2009, 206:287-298.
73. Nice T.J., Deng W., Coscoy L., Raulet D.H. Stress-regulated targeting of the NKG2D ligand Mult1 by a membrane-associated RING-CH family E3 ligase. J Immunol 2010, 185:5369-5376.